Jason Simeone | Research Scientist, Real-World Evidence
Evidera

Jason Simeone, Research Scientist, Real-World Evidence, Evidera

Jason C. Simeone, PhD, MS, is an epidemiologist and Research Scientist in the Real-World Evidence group at Evidera in Waltham, Massachusetts. Dr. Simeone’s experience is focused in the areas of pharmacoepidemiology, drug safety, and outcomes research, and he serves as principal investigator or epidemiologist on database analytics studies and literature reviews. His studies have investigated a variety of therapeutic areas, such as acute coronary syndromes, acute kidney injury/chronic kidney disease, chronic obstructive pulmonary disease, diabetes, Gaucher disease, metastatic cancer, multiple sclerosis, non-alcoholic fatty liver disease, and schizophrenia. His experience includes the use of a variety of administrative claims and electronic health records databases, clinical trial and prospective study data, and government datasets, including Medicare and Medicaid, as well as nationally representative survey data.  Prior to joining Evidera, Dr. Simeone completed a post-doctoral fellowship at the University of Rhode Island, College of Pharmacy. In that capacity, his research focused on the determinants of hypoglycemia among patients with type 2 diabetes. Previous research was also conducted in the areas of geriatric medication management, Medicaid managed care, diabetes, pediatric attention-deficit/hyperactivity disorder, and sleep-disordered breathing. Dr. Simeone has also worked for Quality Partners of Rhode Island, the Medicare Quality Improvement Organization (QIO) for Rhode Island, and Analytic Consulting Solutions. Dr. Simeone received both of his graduate degrees in pharmacoepidemiology and pharmacoeconomics from the University of Rhode Island. He received his bachelor’s degree in biology and economics from Muhlenberg College in Allentown, Pennsylvania.

Appearances:



Pharma Pricing & Market Access USA Day 1 @ 15:50

Safer, Smaller, and More Cost-Efficient Clinical Trials: The Value of Biomarkers for Clinical Trial Enrichment

  • Understanding the Rationale and Importance of Clinical Trial Enrichment
  • Case Study: Use of Existing Study Data to Qualify a Biomarker for Clinical Trial Enrichment in Chronic Obstructive Pulmonary Disease (COPD)
  • Lessons Learned and Implications for Use in Other Therapeutic Areas

back to speakers